RESEPTOR 5-HT7
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Blood sample
What it measured
Main measures
5-HT7 receptor expression on circulating cells
Day 1
Immune response
Other measures (5)
Expression of the 5-HT7 receptor after positive selection of different cell populations from PBMC
Day 15
Immune responseExpression of the different isoforms of the 5-HT7 receptor on PBMC
Day 15
Immune responseFunctional activity of the 5-HT7 receptor on PBMC: protein studies
Day 15
Immune responseFunctional activity of the 5-HT7 receptor on PBMC: mRNA expression studies
Day 15
Immune responseRelationship between Multiple sclerosis treatment on inflammation and serotonin production in serum
Day 15
Blood or spinal fluid markersImmune response
Who could take part
MS (type not specified) · 18 to 50
Inclusion Criteria: * Men and women * Aged between 18 and 50 years old, * With multiple sclerosis already diagnosed and fulfilling the modified Mc Donald criteria * Stable (no relapse in the last 6 months and MRI less than a year old, with no new lesions) and with at least 1 year of treatment with Natalizumab, Ocrelizumab, Teriflunomide or Fumarate * Subject medically fit to give a maximum of 50 ml of extra whole blood * Patient having given their consent to participate in the study Exclusion Criteria: * HIV serology known or discovered during the present episode * Demented patient * Patient treated with corticosteroids in the last month * Non-affiliated person or non-beneficiary of a social security scheme * Uncooperative patient * Patient under legal protection, guardianship or curatorship * Pregnant or breastfeeding women
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Multiple Sclerosis is a chronic autoimmune disease associated with inflammatory response harmful for the Central Nervous System. Immunological imbalance is involved with Th1 and Th17 cells in correlation with a disturbance of regulators mechanisms as Treg cells. Despite years of research, the mechanisms involved remain unclear. Serotonin (5-HT) seems to be play an essential role in developing CNS inflammatory diseases and in particular in MS. Indeed, several studies have shown the anti-inflammatory potential of this neurotransmitter and also its vulnerability in inflammatory context. Moreover, a recent study has shown that 5-HT can reduced CD4 T cells proliferation and pro-inflammatory cytokines released in vitro. Interestingly, treatment, treatment with SSRIs (selective serotonin reuptake inhibitor) in an animal model of MS, on Experimental Autoimmune Encephalomyelitis, was shown to improve the clinical score and promote remission of the disease. Among serotonin receptors, the 5-HT7 receptor, can be considered as an interesting target to treat neurological disorders associated with inflammatory context. Present in humans and mice, this receptor is expressed on the surface of a large number of cells, such as T-lymphocytes, macrophages, dendritic cells as well as on cells of CNS such as neurons, astrocytes and microglia. Given the importance of the positive cells for 5-HT7 receptor, in the inflammatory context observed in multiple sclerosis, the investigators propose to study the receptor expression in blood samples from multiple sclerosis patient.
Papers
Results
Sacramento PM, Monteiro C, Dias ASO, Kasahara TM, Ferreira TB, Hygino J, Wing AC, Andrade RM, Rueda F, Sales MC, Vasconcelos CC, Bento CAM. Serotonin decreases the production of Th1/Th17 cytokines and elevates the frequency of regulatory CD4+ T-cell subsets in multiple sclerosis patients. Eur J Immunol. 2018 Aug;48(8):1376-1388. doi: 10.1002/eji.201847525. Epub 2018 Jun 6.Results
Yuan XQ, Qiu G, Liu XJ, Liu S, Wu Y, Wang X, Lu T. Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats. Neuroimmunomodulation. 2012;19(4):201-8. doi: 10.1159/000334095. Epub 2012 Mar 21.
Loading reviews and guidelines…
History
Started
Mar 2023
Main results due
Jul 2024
Finished
Jul 2024
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error